Back to Search
Start Over
Ancillary benefits of seasonal influenza vaccination in middle-income countries
- Source :
- Vaccine. 39:1892-1896
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- While seasonal influenza vaccines (SIV) remain the best method to prevent influenza-associated illnesses, implementing SIV programs may benefit countries beyond disease reduction, strengthening health systems and national immunization programs, or conversely, introduce new challenges. Few studies have examined perceived impacts of SIV introduction beyond disease reduction on health systems; understanding such impacts will be particularly salient in the context of COVID-19 vaccine introduction. We collected qualitative data from key informants-Partnership for Influenza Vaccine Introduction (PIVI) contacts in six middle-income PIVI vaccine recipient countries-to understand perceptions of ancillary benefits and challenges from SIV implementation. Respondents reported benefits associated with SIV introduction, including improved attitudes to SIV among risk groups (characterized by increased demand) and perceptions that SIV introduction improved relationships with other ministries and collaboration with mass media. Challenges included sustaining investment in SIV programs, as vaccine supply did not always meet coverage goals, and managing SIV campaigns.
- Subjects :
- Influenza vaccine
viruses
animal diseases
030231 tropical medicine
Developing country
Qualitative property
Context (language use)
Disease
Seasonal influenza
03 medical and health sciences
0302 clinical medicine
Environmental health
Influenza, Human
Humans
030212 general & internal medicine
Developing Countries
Mass media
General Veterinary
General Immunology and Microbiology
Immunization Programs
business.industry
Vaccination
Public Health, Environmental and Occupational Health
virus diseases
Infectious Diseases
Influenza Vaccines
Molecular Medicine
Business
Subjects
Details
- ISSN :
- 0264410X
- Volume :
- 39
- Database :
- OpenAIRE
- Journal :
- Vaccine
- Accession number :
- edsair.doi.dedup.....6aee6987b4167d7ad58719a2e7795bd8
- Full Text :
- https://doi.org/10.1016/j.vaccine.2021.02.048